Immunomodulatory and direct activities of ropeginterferon alfa‐2b on cancer cells in mouse models of leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15376
Abstract: Although ropeginterferon alfa‐2b has recently been clinically applied to myeloproliferative neoplasms with promising results, its antitumor mechanism has not been thoroughly investigated. Using a leukemia model developed in immunocompetent mice, we evaluated the direct cytotoxic… read more here.
Keywords: ropeginterferon alfa; alfa cancer; mice;